Cambridge Healthtech Institute’s 5th Annual

Agonist Immunotherapy Targets

Stepping on the Gas with Costimulatory Agents

April 11-12, 2019


The immunotherapies industry is currently dominated by antagonist antibodies such as PD-1 and CTLA-4. However, it is clear that antagonists alone are not enough to elicit response in the majority of patients, hence a rising interest in agonists targets.

CHI’s Agonist Immunotherapy Targets conference will examine these modalities and their treating disease. Agonists showing the most promise, including OX40, CD27, GITR, and 4-1BB, will be covered in clinical case studies by examining the data as well as the biology and mechanisms. Emerging agonists, including TNFR receptors, ICOS, STING, and VISTA will also be discussed. Focus will be given throughout to potential combination immunotherapies to ensure durable antitumor response. Overall, this event will emphasize strategies for target discovery to ensure continued growth and success for immunotherapies.

Preliminary Agenda


OX40: Is Timing Everything?

Brendan Curti, MD, Director of the Melanoma Program, Cytokine and Adoptive Immunotherapy and Genitourinary Oncology Research, Providence Portland Medical Center

Combination Immunotherapy

William L. Redmond, PhD, Associate Member, Laboratory of Cancer Immunotherapy, Director, Immune Monitoring Laboratory, Providence Portland Medical Center

Agonist Bispecific Antibodies Delivering the Next Immuno-Oncology Breakthrough

Mihriban Tuna, PhD., Vice President, Drug Discovery, F-star Biotechnology Ltd.

ATOR-1017, A 4-1BB Antibody Developed for Tumor Directed Immunotherapy of Cancer

Peter Ellmark, PhD, Vice President, Discovery, Alligator Bioscience

PD1-Fc-OX40L for Cancer Immunotherapy

Taylor Schreiber, PhD., Chief Scientific Officer, Research & Development, Shattuck Labs, Inc.


The Appeal of The TNFR2 Target for Immunotherapy: Tregs and Tumor Oncogenes

Denise L Faustman, M.D., PhD., Director of Immunobiology, Massachusetts General Hospital, Associate Professor of Medicine, Harvard Medical School

Development of TNF Superfamily Agonists: 4-1BB Ligand Fusion Shows Anti-Tumor Activity In Vivo

Andreas Raue, PhD., Associate Director, Research, Merrimack Pharmaceuticals

A Novel Systemically Delivered STING Pathway Agonist Therapy Demonstrates Robust Anti-Tumor Efficacy in Multiple Murine Cancer Models

Christopher Thanos, PhD., CEO, Actym Therapeutics

* The program is subject to change without notice, due to unforeseen reason.

Choose your language
Traditional Chinese
Simplified Chinese

Premier Sponsors

View By: